Anne Renee Van Der Vuurst De Vries
About Anne Renee Van Der Vuurst De Vries
Anne Renee Van Der Vuurst De Vries serves as the Director of Product Validation at Sonoma Biotherapeutics, a position she has held since 2020. With extensive experience in the biopharmaceutical industry, she has previously worked in various roles at companies such as Celgene, Novo Nordisk, and Amgen.
Current Role at Sonoma BioTherapeutics
Anne Renee Van Der Vuurst De Vries serves as the Director of Product Validation at Sonoma BioTherapeutics. She has held this position since 2020, contributing to the company's efforts in biotherapeutic product development. Based in the Greater Seattle Area, her role involves overseeing the validation processes to ensure product efficacy and safety.
Previous Experience at Celgene
Prior to her current role, Anne worked at Celgene in various capacities. She served as Director for eight months in 2019 and held the position of Senior Principal Scientist from 2018 to 2019. Additionally, she was a Principal Scientist in Immuno-Oncology from 2015 to 2018. Her tenure at Celgene focused on advancing therapeutic strategies and product development.
Background in Immunology and Inflammation
Anne has extensive experience in the field of immunology and inflammation. She worked at Novo Nordisk A/S as a Principal Scientist in Discovery Immunology from 2013 to 2014 and as a Senior Scientist from 2010 to 2013. Her role at Addex Pharmaceuticals as Lab Head for the Inflammation Business Unit further solidified her expertise in this area.
Educational Background
Anne Renee Van Der Vuurst De Vries studied at Utrecht University, where she gained foundational knowledge in her field. She also attended the University of Amsterdam, further enhancing her academic credentials. Her education has played a significant role in her professional development and expertise in biotherapeutics.
Career Progression in Biopharmaceuticals
Anne's career spans over two decades in the biopharmaceutical industry. She began her career as a Postdoc at Immunex from 2000 to 2003. She then held various senior roles at Amgen and other companies, including Addex Pharmaceuticals and Novo Nordisk A/S. This progression highlights her commitment to advancing therapeutic innovations.